Editorial: FibroTest to predict liver-related mortality in NAFLD. Should this change the diagnostic algorithm in NAFLD?

Bush AM; Torres DM

doi:10.1111/apt.15036

Editorial: FibroTest to predict liver-related mortality in NAFLD. Should this change the diagnostic algorithm in NAFLD?

MeSH — NLM indexing Algorithms Hepatitis C, Chronic Humans Liver Liver Diseases, Alcoholic Non-alcoholic Fatty Liver Disease Prognosis

Staff actions

Download PDF

Files are for authorised use within BioPredictive partner channels only.

Fibrotest Actitest Editorial Independent Group United States

Authors (2)

Bush AM — Walter Reed National Military Medical Center, Bethesda, Maryland.
Torres DM — Walter Reed National Military Medical Center, Bethesda, Maryland.

Citation

Bush AM, Torres DM. Editorial: FibroTest to predict liver-related mortality in NAFLD. Should this change the diagnostic algorithm in NAFLD?. Aliment Pharmacol Ther. 2018;48(11-12):1319-1320. doi:10.1111/apt.15036.

Identifiers

DOI: 10.1111/apt.15036
PMID: 30488622

Tests

Liver diseases

Liver injuries

Region

Editorial: FibroTest to predict liver-related mortality in NAFLD. Should this change the diagnostic algorithm in NAFLD?

More on the same topic

Diagnostic performance of FibroTest-ActiTest, transient elastography, and the fibrosis-4 index in patients with autoimmune hepatitis using histological reference.

Metabolic dysfunction-associated steatotic liver disease (MASLD) biomarkers and progression of lower limb arterial calcification in patients with type 2 diabetes: a prospective cohort study.

Three Neglected STARD Criteria Reduce the Uncertainty of the Liver Fibrosis Biomarker FibroTest-T2D in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

Toward non-invasive assessment strategies in autoimmune hepatitis.

Accuracy of prognostic serological biomarkers in predicting liver fibrosis severity in people with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of over 40,000 participants.

Non-alcoholic fatty liver disease biomarkers estimate cardiovascular risk based on coronary artery calcium score in type 2 diabetes: a cross-sectional study with two independent cohorts.